Compare AstraZeneca plc (AZN) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares Core MSCI EAFE ETF — how do they compare? AstraZeneca plc trades at $157.97 (market cap $248.14B), while iShares Core MSCI EAFE ETF trades at $100.9. The key difference: AstraZeneca plc pays a 2.01% dividend while iShares Core MSCI EAFE ETF pays none, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | IEFA | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $209.48 | $101.09 |
52-Week Low | $147.06 | $84.72 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
IEFA trades at $100.895, up 0.36% today, with a bullish technical signal from moving averages and strong trend momentum indicated by ADX. The fund focuses on developed international markets excluding the U.S. and Canada, offering diversification benefits and a dividend yield of 3.30% as noted by The Motley Fool on June 13, 2026. Recent news highlights its cost efficiency compared to peers like EFA, with an expense ratio of 0.07%.
Outlook is positive due to defensive inflows and Fed cut potential, but risks include capped upside from covered call strategies and concentration in non-U.S. markets. Analyst sentiment is mixed, with some favoring broader ETFs like VXUS for higher returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →
